Archive for the ‘research’ Category

1 in 3 Cancer-Free: Ivermectin Trial Stuns, but RESET-5 Aims Even Higher

https://zenodo.org/records/19455636

Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort

Authors/Creators

Nicolas Hulscher, MPH1, 2, Kelly Victory, MD2, James A. Thorp, MD2, Drew Pinsky, MD2, Alejandro Diaz-Villalobos, MD2, Peter Gillooly, MSc2, Foster Coulson2, Melissa Annazone2, Chloe Radesi2, Jessica Brooks2, Peter A. McCullough, MD, MPH1, 2, Harvey Risch, MD, PhD3, 2

April 7, 2026

Description

Abstract

Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer stem cells. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol.

Methods: We analyzed a prospective observational cohort of 197 cancer patients who were prescribed ivermectin and mebendazole off-label through a telemedicine platform by licensed U.S. healthcare providers. Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. As part of a clinical program evaluation, data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) to evaluate self-reported cancer outcomes, medication adherence, and adverse events. 95% confidence intervals (CI) were calculated for primary outcome measures using the Wilson score method. Dose-stratified analyses for outcomes and safety were conducted using Chi-square statistics.

Results: The cohort represented a diverse clinical profile of cancer patients, with mean age of 67 years and nearly balanced sex distribution (52.3% male, 47.7% female). Cancer types included prostate (27.9%), breast (18.3%), lung (8.6%), colon (5.1%), urologic (4.6%), pancreatic (3.0%), liver (2.5%), gynecologic (2.5%), and hematologic (2.5%) malignancies. At enrollment, participants had a median duration since initial diagnosis of 1.2 years, with 37.1% experiencing active disease progression. At 6-month follow-up, medication adherence was high with 86.9% of participants completing the full initial 90-capsule ivermectin-mebendazole prescription and 66.4% remaining on the protocol at 6 months. The Clinical Benefit Ratio (CBR) was 84.4% (95% CI: 77.0–89.8%). Notably, 48.4% (95% CI: 39.7–57.1%) of the cohort reported the strongest positive outcomes, consisting of regression (15.6%; 95% CI: 10.2–23.0%) or no current evidence of disease (NED, 32.8%; 95% CI: 25.1–41.5%). Disease stability was reported to be maintained in 36.1% (95% CI: 28.1–44.9%) of participants, while 15.6% (95% CI: 10.2–23.0%) reported disease progression. While 25.4% reported mild side effects (primarily gastrointestinal), 93.6% of those affected continued treatment through minor dose adjustments. Some participants reported concurrent conventional therapies, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%), as well as adjunctive interventions such as supplement use (49.2%), dietary modification (37.7%), and other integrative approaches.

Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumor regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, given the observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials are warranted to validate these observations and further define optimal dosing strategies. (Go to link for full-length study)

_____________

**Comment**

http://

Could These Overlooked Drugs Be a Cancer Game-Changer?

Dr. Ken Stoller, April 12, 2026

For a wonderful breakdown of the study:  https://justusrhope.substack.com/p/1-in-3-cancer-free-ivermectin-trial?  Excerpt:

Dosages and Concurrent Therapies

Patients were prescribed the medications off-label through a telemedicine platform. They received compounded oral capsules containing:

  • 25 mg of Ivermectin
  • 250 mg of Mebendazole

The study noted that these were not strictly monotherapies. Many patients were undergoing concurrent conventional treatments, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%). Additionally, many used adjunctive interventions such as supplements (49.2%) and dietary modifications (37.7%).

Study Completion and Attrition

Of the initial 197 patients, 75 patients failed to complete the study (meaning they did not complete the 6-month follow-up survey).

  • A total of 122 participants completed the 6-month follow-up survey, resulting in a 61.9% response rate.
  • Among the 122 who responded, adherence was high: 86.9% completed the full initial 90-capsule prescription, and 66.4% chose to remain on the protocol at the 6-month mark.

Clinical Outcomes and Tolerability

The authors reported an overall Clinical Benefit Ratio (CBR) of 84.4% among the 122 patients who completed the survey. The self-reported outcomes broke down as follows:

  • No Evidence of Disease (NED): 32.8%
  • Disease Stabilization: 36.1%
  • Tumor Regression: 15.6%
  • Disease Progression: 15.6%

Within the article, Justuserhope asked AI to evaluate the benefit of adding one agent at a time from the RESET-5 Protocol (Mebendazole, ivermectin, sulforaphane, metformin, and aged garlic extract) to the Hulscher et. al study.  The full RESET-5 reduces the likelihood of resistance development, enhances immune function, and depletes tumors of a critical survival tool – compensatory glutathione production.

The full RESET-5 Protocol boosts improvement even further by 30-40%.

_____________

**Comment**

For those of you studying this, 25 mg of ivermectin and 250mg of Mebendazole are considered pretty low dosages.  Many patients are taking much more than that, so the fact they are getting such great improvement with such low dosages is fairly amazing.  Lower dosages typically mean lower side-effects so this should be safe for nearly all to take.  Share with your doctor and work together to get the best fit.

For more:

Category:

Cancer, research, Treatment

Tools, Hope, & Healing in Lyme Disease: Dr. Joseph Jemsek

http://

Tools, Hope & Healing in Lyme Disease with Dr. Joseph Jemsek

Mar 24, 2026
A webinar and Q&A on tools, hope and healing for those affected by Lyme disease with special guest Dr. Joseph Jemsek.
Sponsored by the National Lottery Community Fund and facilitated by Lyme Disease UK Patient Ambassador Morven-May MacCallum.
Joseph Jemsek, MD, trained as an infectious disease specialist and dedicated the first 20 years of his practice to patients with HIV/AIDS. In the early 2000s, an influx of patients from all over the United States started flooding his practice, the Jemsek Clinic, complaining of chronic symptoms of Lyme disease. This was the start of an unexpected new chapter that would change the course of Lyme disease treatment and of Dr. Jemsek’s own life. Dr. Jemsek evaluated over 15,000 cases of Lyme and other tick-borne illnesses and introduced dozens of pioneering treatment innovations.
You may sign up for Dr. Jemsek’s newsletter, Choose Life Over Lyme!, where he’ll be sharing twenty-five years of insights from his work decoding Lyme disease, at ChooseLifeOverLyme.com
You can access his guide Self-Help Tools to Manage Lyme Borreliosis Complex co-created with Lyme Disease UK here: lymediseaseuk.com/wp-content/uploads/2026/03/Self-Help-Tools-2026-.pdf
_____________
**Comment**
Highly recommend!  Dr. Jemsek is not treating patients anymore but his expertise is phenomenal.  He was also persecuted for prescribing long term antibiotics to treat chronic Lyme by the North Carolina Medical Board which restricted his medical license, but was vindicated. You won’t regret the time you spend watching this.
For more:

Category:

Lyme, research, Ticks, Treatment

Lost Signals: Study Shows VAERS Buries Vaccine Harm & CDC, FDA Admit to Using ‘Mostly Useless’ Tool

https://imahealth.substack.com/p/lost-signals-new-study-shows-how?

Lost Signals: New Study Shows How VAERS Buries Vaccine Harm

VAERS already catches only a fraction of vaccine harm. New research by Jessica Rose reveals the system is losing even more data to fixable flaws.
Independent Medical Alliance
Mar 31, 2026

America’s vaccine safety system already catches only a fraction of the harm that occurs. That much has been known for years. VAERS is a passive reporting system, and most adverse events are never reported at all.

But what happens to the data that does make it in?

A new study by Jessica Rose, a computational biologist, immunologist, and IMA Senior Fellow, shows that VAERS is losing critical safety data from the inside. The system’s own infrastructure is so outdated and poorly maintained that real signals of harm are being buried by fixable data problems. When Rose cleaned the data and reassembled what had been scattered, she found safety signals for fetal loss and cardiac arrest that had been there all along, invisible to anyone using the system as designed.

“The main claim to fame here is that I pointed out some of the problems inherent in VAERS that most people, unless they’re using it as part of data analysis, wouldn’t really know about.” — Jessica Rose

📖 Read and Download the Full Paper

Minimizing Signal Loss and Optimizing Pharmacovigilance in VAERS (JIM Vol. 2, No. 2, 2026) — Author: Jessica Rose

👉 Visit the Journal of Independent Medicine to create a free account and download the full article.

What’s Broken in VAERS?

VAERS was built in the 1980s and has operated with the same basic infrastructure ever since. Reports are submitted through an online form that takes about 30 minutes to fill out. There are no pull-down menus. No standardized formats for vaccine lot numbers or dates. The form has session timeouts that can erase a report before it’s finished. And the system creates multiple IDs for the same patient rather than linking a serious reaction to a follow-up death report.

The people filing reports experience these problems every time they sit down to submit one. But the people relying on the data to detect harm may never realize what’s being lost.

Rose showed just how small the fixes can be. Two simple corrections to vaccine lot numbers (capitalizing letters and removing stray spaces)  recovered 8,871 reports that had been invisible to analysis. Not because the data was missing. Because the system couldn’t recognize its own records.

(See link for article and video)

_____________

https://childrenshealthdefense.org/defender/cdc-fda-admitted-mostly-useless-tool-detect-covid-vaccine-safety-signals/

CDC, FDA Admitted to Using ‘Mostly Useless’ Tool to Detect COVID Vaccine Safety Signals

Federal health officials knew the statistical tool they relied on to look for COVID-19 vaccination safety signals in VAERS was “mostly useless,” according to internal documents obtained by Sen. Ron Johnson and analyzed by scientists at Children’s Health Defense. CDC and FDA researchers used the tool anyway to create analyses they tried to publish that supported the vaccines’ safety.

by Suzanne Burdick, Ph.D.
April 1, 2026
files and covid vaccine

Federal health officials knew that the statistical tool they relied on to look for COVID-19 vaccination safety signals in the Vaccine Adverse Event Reporting System (VAERS) was “mostly useless,” according to internal documents obtained by Sen. Ron Johnson (R-Wis.) and analyzed by scientists at Children’s Health Defense (CHD).

The documents show that officials at the Centers for Disease Control and Prevention (CDC) and U.S. Food and Drug Administration (FDA) internally acknowledged that the tool — empirical Bayesian (EB) data mining — had “blind spots” that rendered it “mostly useless” for picking up on safety signals of COVID-19 vaccines.

Yet, the agencies used the method in analyses and attempted to publish findings from those analyses — including studies that supported the safety of COVID-19 vaccines.

Karl Jablonowski, Ph.D., CHD senior research scientist who analyzed the documents, told The Defender:

“Imagine a night watchman has to find something on the ground. But instead of holding a flashlight, he is wearing sunglasses. In the morning, he says he didn’t find anything. That’s true, but it’s because he was using a tool that impeded his ability to see.”

The records obtained by Johnson’s office include emails between CDC and FDA researchers from 2021 to 2023, along with draft manuscripts and peer reviewer comments.

In one case, researchers sought to publish an analysis in The Lancet Infectious Diseases using EB data mining on early COVID-19 vaccine data. They dropped the plan only after a reviewer wrote that the likelihood of detecting a safety signal using the method was “likely close to zero.”

FDA official Dr. David Menschik, who initially was a co-author on the paper, wrote to the study’s lead author in December 2021 saying he knew the method was essentially useless.

“We acknowledged this in the limitations and understand that there is a considerable bias toward the null when using our data mining methods in this current, unprecedented situation,” he wrote.  (See link for article)

For more:

Category:

Activism, research, vaccines

GBS as an Initial Manifestation of Lyme Disease: Diagnostic Challenges

https://www.cureus.com/articles/467640-guillain-barr-syndrome-as-the-initial-manifestation-of-lyme-disease-diagnostic-challenges

Guillain-Barré Syndrome as the Initial Manifestation of Lyme Disease: Diagnostic Challenges

Ahmed Elnour • Naveed Sultan • Abdul Monem • Khalid Ghalib

Published: March 20, 2026

DOI: 10.7759/cureus.105552

Open Access
Peer-Reviewed

Cite this article as: Elnour A, Sultan N, Monem A, et al. (March 20, 2026) Guillain-Barré Syndrome as the Initial Manifestation of Lyme Disease: Diagnostic Challenges. Cureus 18(3): e105552. doi:10.7759/cureus.105552

Abstract

Lyme disease is a common tick-borne infection in the United States and Europe that may involve the nervous system during the disseminated stage. Guillain-Barré syndrome (GBS) is an acute immune-mediated polyneuropathy usually triggered by infection; however, its association with Borrelia burgdorferi is uncommon and can pose diagnostic challenges.

We report the case of a previously healthy 61-year-old female patient who presented with progressive ascending weakness and areflexia suggestive of GBS. During hospitalisation, she developed bilateral facial nerve palsy, prompting further evaluation. Cerebrospinal fluid (CSF) findings and electrophysiological studies supported acute inflammatory demyelinating polyneuropathy, while serologic testing confirmed Lyme disease. The patient received intravenous immunoglobulin (IVIG) followed by intravenous ceftriaxone and achieved complete neurological recovery.

This case emphasizes the need to consider Lyme disease in patients presenting with acute inflammatory neuropathy, particularly in endemic regions, as early diagnosis and targeted therapy can significantly improve outcomes.

_____________

**Comment**

The researchers state that the association between GBS with Lyme is uncommon, yet nobody is counting cases!  How can they know?

Answer: they don’t.  They shouldn’t state things that are pure conjecture.

For more:

Category:

Lyme, research, vaccines, Viruses

A Bacterial Toxin Facilitating Chronic Infection

https://www.biozentrum.unibas.ch/news/detail/a-bacterial-toxin-facilitating-chronic-infection

A bacterial toxin facilitating chronic infection

Some pathogens persist in the body causing chronic infections. Researchers led by Prof. Christoph Dehio and Prof. Tilman Schirmer at the Biozentrum, University of Basel, have now discovered a mechanism of highly selective targeting of host proteins by a bacterial toxin that is critical for the bacteria to establish chronic infection. The study recently published in “PNAS” provides new insights into the activity and function of bacterial toxins.

The bacterial pathogen Bartonella (purple) in interaction with human host cells (green).

When pathogens invade our body the immune system is put on alert. The body’s immune cells are recruited to the site of infection and an inflammatory reaction is initiated to rapidly eliminate the invaders. Some pathogens, however, have developed clever strategies to evade this line of defense. Bartonella is one of them. Manipulating the body’s cells to its advantage enables the pathogen to persist in the host.

Researchers led by Prof. Christoph Dehio and Prof. Tilman Schirmer at the Biozentrum, University of Basel, have now elucidated an important mechanism how Bartonella  ensures long-term survival in the body. It injects a bacterial toxin into the body’s cells, which deactivates a specific group of proteins important for the immune response. This mechanism is vital for the pathogen’s capacity to cause chronic infection.

Bacterial toxins modulate signaling pathways in host cells

In mammalian cells, so-called Rho GTPases serve as molecular ON-OFF switches controlling a wide range of signaling pathways and thus pivotal cellular activities, such as cell movement, cytoskeletal dynamics and also the innate immune response. Due to their central regulatory role, this protein family is a target of choice for bacterial toxins. These thwart cellular signaling and facilitate the pathogen to survive in the host. However, many bacterial toxins targeting multiple GTPases cause massive collateral damage to the cells and typically limits pathogen survival to the acute infection phase.

Bartonella subtly colonizes the host

In contrast, Bartonella hijacks the host in a “gentle” way. The pathogen employs toxins that very selectively target host cell functions. In doing so, Bartonella reduces the efficacy of the immune system without causing collateral damage, enabling the pathogen to persist in the host. “We have now been able to elucidate the mechanism of highly selective recognition of specific host proteins by the Bartonella toxin Bep 1,” says Dehio. “Bep 1 exclusively targets proteins of the Rac-subfamily but not the other members of the large Rho GTPase family that are typically inactivated all together by toxins with primary acute infection patterns.”

Elucidating bacterial toxin selectivity

Employing a combination of structural analysis, modeling and biochemical methods, the researchers have now been able to elucidate the mechanism underlying this unique target selectivity. “The spectrum of target proteins is determined by large on shape complementarity and the electrostatic interactions of a short structural element in Bep1 with two protein segments unique to the Rac-subfamily,” explains Dehio. This simple, yet elegant, evolutionary treat equips Bartonella with a precise molecular tool to selectively interfere with host signaling.

Original publication:
Nikolaus Dietz, Markus Huber, Isabel Sorg, Arnaud Goepfert, Alexander Harms, Tilman Schirmer and Christoph Dehio. Structural basis for selective AMPylation of Rac-subfamily GTPases by Bartonella effector protein 1 (Bep1). Proceedings of the National Academy of Sciences (PNAS) 2021

Contact: Communications, Katrin Bühler

_____________

**Comment**

This right here, is why patients remain sick.  We are typically filled with multiple stealth pathogens with the capability to quietly impede the normal mechanisms the body uses to clear infections.  Sadly, Bartonella is not the only organism capable of this guerrilla warfare – Borrelia, the causative agent of Lyme disease also changes its outer surface protein to remain cloaked and accepted by the immune system.  If antimicrobials are used, it also has the ability to shape shift and go into a dormant state only to reemerge when conditions are conducive for growth.

When will mainstream medicine get the memo?

For more:

 

Category:

Bartonella, research